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Transmembrane domainPathogenic simian–human immunodeﬁciency viruses (SHIV) contain HIV-1 Vpu and SIV Nef, both shown to
counteract BST-2 (HM1.24; CD317; tetherin) inhibition of virus release in a species-speciﬁc manner. We
show that human and pig-tailed BST-2 (ptBST-2) restrict SHIV. We found that sequential “humanization” of
the transmembrane domain (TMD) of the pig-tailed BST-2 (ptBST-2) protein resulted in a ﬂuctuation in
sensitivity to HIV-1 Vpu. Our results also show that the length of the TMD in human and ptBST-2 proteins is
important for BST-2 restriction and susceptibility to Vpu. Taken together, our results emphasize the
importance of tertiary structure in BST-2 antagonism and suggests that the HIV-1 Vpu transmembrane
domain may have additional functions in vivo unrelated to BST-2 antagonism.gy, Molecular Genetics, and
as City, Kansas 66160, USA.
.
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Human bone marrow stromal cell antigen 2 (BST-2; HM1.24;
CD317 or tetherin) was recently identiﬁed as a potent inhibitor of the
release of multiple enveloped viruses including human immunode-
ﬁciency virus type I (HIV-1) and simian immunodeﬁciency virus (SIV)
(Jouvenet et al., 2009; Kaletsky et al., 2009; Neil et al., 2008; Van
Damme et al., 2008).While the exact cellular function of human BST-2
(hBST-2) in the human host is unclear, it has been shown to play a role
in regulating the growth and development of B cells, to be involved in
the organization of the subapical actin cytoskeleton in polarized
epithelial cells (Rollason et al., 2009), andmost recently to function as
a ligand for ILT7, a receptor that inhibits IFN production from
plasmacytoid dendritic cells (Cao et al., 2009). BST-2 is an interfer-
on-induced, lipid raft-associated, type II integral membrane protein
with an unusual topology that is similar in membrane orientation to a
neuro-pathogenic form of the prion protein (PrP) (Kupzig et al.,
2003). It contains a short cytoplasmic N-terminus followed by a
transmembrane domain (TMD), a central extracellular domainpredicted to form a coiled-coil structure, and a C-terminal cleavage
site predicted to form a glycosyl-phosphatidylinositol (GPI) anchor
(Ishikawa et al., 1995; Kupzig et al., 2003). This topology supports
membrane-spanningmodels of restrictionof virion release, inwhich the
proteinwould form dimers providing a physical, protease-sensitive link
between the cellular andviralmembranes (Perez-Caballero et al., 2009).
This model is supported by evidence that hBST-2 is incorporated into
nascent virions and that the formation of cysteine-linked dimers is
required for hBST-2 restriction of HIV-1 virion release (Ali et al., 2010;
Andrew et al., 2009; Fitzpatrick et al., 2010; Habermann et al., 2010;
Perez-Caballero et al., 2009).
Several studies have provided evidence that viruses including HIV-1
and SIV have evolved to acquire activity against the anti-viral properties
of BST-2. The HIV-1 group M Vpu proteins counteract speciﬁcally the
restriction of human, chimpanzee and gorilla BST-2 proteins, with the
exception of Vpu from strains JR-CSF and YU-2, which also antagonized
BST-2 proteins derived from Greater-spot nosed and African green
monkeys (Jouvenet et al., 2009; Neil et al., 2008; Sauter et al., 2009; Van
Damme et al., 2008). The Nef proteins isolated from SIVmac, SIVcpz, SIVgor,
and SIVagm also antagonize the effects of certain non-humanprimate BST-
2 proteins, including those isolated from rhesus (rhBST-2) and pig-tailed
(ptBST-2) macaques (Jia et al., 2009; Sauter et al., 2009; Zhang et al.,
2009). Similar to other known intrinsic viral restriction factors such as
the APOBEC3 and TRIM families of proteins, the ability of speciﬁc viral
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2009; Jia et al., 2009; McNatt et al., 2009; Zhang et al., 2009). Speciﬁc
domains and amino acids within these proteins mediate this speciﬁcity,
allowing small evolutionary changes to confer susceptibility to cross-
species infection (Gupta et al., 2009; Jia et al., 2009; McNatt et al., 2009;
Yap et al., 2005; Zhang et al., 2009). The interaction of Vpu with hBST-2
involves the TMDs of both proteins (Douglas et al., 2009; McNatt et al.,
2009; Rong et al., 2009). Several studies have identiﬁed amino acids
within the human, rhesus and tantalus monkey BST-2 proteins required
for Vpu sensitivity/resistance. These studies found several combinations
of substitutions within the transmembrane domain of hBST-2 that
reduced susceptibility to Vpu, including delGI,T45I (where glycine and
isoleucine residues at positions 25 and 26 were deleted in combination
with the substitution of a threonine at position 45with an isoleucine) and
delGI, I33V, I36L (where the glycine and isoleucine residues at positions
25 and 26 were deleted in combination with the substitution of the
isoleucine at position 33 with a valine and mutation of the isoleucine at
position 36 to a leucine). These studies also noted the importance of the
proline residue at position 40 in sensitivity to Vpu (McNatt et al., 2009).
More recent studies focused on the speciﬁc role of amino acidswithin the
BST-2 proteins from non-human primates in the susceptibility and
resistance to SIVmac Nef proteins. Several groups obtained similar results
that identiﬁed an amino acidmotif that is present within the cytoplasmic
domain (D/GIWK14–17) of pig-tailed and rhBST-2 as important for SIVNef
susceptibility. These investigators showed that this motif could be
inserted into the hBST-2 protein and impart susceptibility to the SIV Nef
protein (Jia et al., 2009; Zhang et al., 2009).
Simian–human immunodeﬁciency viruses (SHIVs) have been
used extensively for in vivo studies to understand the role of HIV-1
Vpu and Env proteins as well as other SIV proteins in viral
pathogenesis. These chimeric viruses express both the HIV-1 Vpu
and SIVmac Nef proteins shown to counteract BST-2 orthologues
from human and non-human primates and possibly represent a
useful virus to study these interactions. In this study, we examined
the characteristics and anti-viral activities of BST-2 proteins from
humans and pig-tailed macaques with speciﬁc amino acid
exchanges in the context of SHIVs lacking the HIV-1 vpu gene, the
SIV nef gene, or both. Our results indicate that the transmembrane
domain is a determinant of HIV-1 Vpu susceptibility, however, the
length of the domain may play more of a role in this rather than
speciﬁc amino acids and or combinations of residues.
Results
Comparison of the sequence of pig-tailed and rhesus bst-2 genes
We ampliﬁed and sequenced the bst-2 genes from ﬁve rhesus
macaques (CX54, AH64, AS05, AS34 and AS89) and seven pig-tailed
macaques (CC8X, W004, W005, W006, W007, W013, and W018). The
genes isolated from the rhesus macaques exhibited considerable
variability compared to genes isolated frompig-tailedmacaques, most
notably in the N-terminal regions (Fig. 1). We observed a 50:50
distribution of arginine and cysteine at position 9, a 60:40 ratio of
aspartic acid to glycine at position 14, a 70:30 distribution of valine to
isoleucine at position 29 and ﬁnally an 80:20 ratio of leucine to proline
at position 43. In contrast the pig-tailed sequences did not show
signiﬁcant variability with the exception of one sequence that had a
leucine instead of a methionine at position 13. Based on the sequence
analysis, we cloned the ptbst-2 gene for expression studies.
Analysis of human and ptBST-2 mutants
We constructed a series of mutations in the human (hBST-2) and
pig-tailed macaque (ptBST-2) bst-2 genes. These are presented in
Fig. 2. We ﬁrst examined the expression of each mutant BST-2 protein
by transfection of 293 cells with vectors expressing each mutantprotein and subsequent Western blot analysis of the cell lysates
(Fig. 3). Substitution of the leucine and glycine residues at positions
24 and 25 in hBST-2 with alanines or isoleucines (hBST-2LG/AA or
hBST-2LG/II) consistently resulted in higher levels of expression,
suggesting that these mutations may increase the half-life of these
proteins. The only other protein with altered expression was the
ptBST-2(ΔDDWIK/+LG). This amino acid substitution resulted in
decreased protein expression, which could be due to altered stability
of the protein and was not further studied.
SHIV can serve as models for studying BST-2 mediated restriction
In order to examine the ability of the wild-type hBST-2 and ptBST-2
proteins to restrict virus release, we used parental SHIVKU-2MC4 to
construct three SHIVs that did not express either HIV-1 Vpu (SHIVΔVpu),
SIV Nef (SHIVΔNef) or both proteins (SHIVΔVpu/ΔNef). HEK 293 cells were
co-transfected with plasmids expressing one of the four SHIVs and each
of the BST-2 constructs. At 48 h post-transfection, the supernatants were
collected and cleared by centrifugation, the cells were lysed and the
nuclei and cellular debris cleared by centrifugation. The supernatants and
cell lysates were used to quantify the percent p27 antigen release from
cells and the supernatants were also evaluated for the number of
infectious doses (TCID50) (Fig. 4). The percent release of p27 in the
context of each SHIV in the presence and absence of each BST-2 protein is
shown in Fig. 4A. All samples were normalized to their respective SHIV
empty vector controls. Signiﬁcance in the restriction of p27 release for the
SHIVKU-2MC4 samples was determined with respect to the parental
SHIVKU-2MC4 empty vector control using a Student's t-test (▲). Signiﬁ-
cance in the restriction of p27 release for the SHIVΔVpu, SHIVΔNef, and
SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in
the presence of each respective BST-2 using a Student's t-test (*). The
level of infectious virus released was determined using TZM-bl indicator
cells (Fig. 4B). The results are represented as the average log10 infectious
units. Signiﬁcance in the restriction of infectious units released was
determined with respect to the appropriate empty vector control (•)
since Nef has signiﬁcant effects on virion infectivity that are not
associated with BST-2 incorporation (Aiken and Trono, 1995; Chowers
et al., 1994). All four SHIVs exhibited similar p27 release in the absence of
any BST-2 protein. In the presence of hBST-2, SHIVΔVpu and SHIVΔVpu/ΔNef
viruses exhibited a signiﬁcant decrease in p27 release from cells while
SHIVΔNef had no decrease in p27 release. Similar results were observed in
the infectious units assay. In the presence of ptBST-2 protein, only
SHIVΔNef and SHIVΔVpu/ΔNef showed a decrease in p27 release as well as
infectious units released. These results are in congruence with those
published by other investigators that found that hBST-2 is susceptible to
HIV-1 Vpu and ptBST-2 is sensitive to the SIV Nef (Neil et al., 2008; Van
Damme et al., 2008; Zhang et al., 2009), indicating that these SHIVs can
serve as models for studying the individual and additive effects of
different BST-2 proteins.
Mutant ptBST-2 antagonism of SHIV release
Previous studies showed that the transmembrane domain of the
hBST-2 protein dictates its interaction with and susceptibility to
HIV-1 Vpu (McNatt et al., 2009; Gupta et al., 2009; Rong et al., 2009).
We determined if cumulative consecutive amino acid substitutions
in the transmembrane domain of the ptBST-2 would result in a
gradual increase in sensitivity to Vpu. We generated a library of
ptBST-2 constructs with successive “humanizing” amino acid
substitutions starting from the amino terminal end of the TMD
with an insertion of two amino acids, a leucine and a glycine, at
positions 29 and 30. We transfected each construct into 293 cells in
conjunction with one of four different simian–human immunode-
ﬁciency virus expressing plasmids. The supernatants and cell lysates
were used to quantify the percent p27 antigen release from cells and
the supernatants were also evaluated for the number of infectious
Fig. 1. Sequence analysis of bst-2 genes ampliﬁed from rhesus (A) and pig-tailed (B) macaques. RNA was isolated from either spleen tissue or PBMC from ﬁve rhesus macaques and
seven pig-tailed macaques. The bst-2 gene was ampliﬁed from each of these samples and bulk sequenced. The sequences obtained from the rhesus macaques are presented along
with the sequences of rhBST-2 from the genomic database. The BST-2 proteins used in this study for both rhesus and pig-tailed macaques were used as references and the dashes
represent similar identity.
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Fig. 2. The amino acid sequence of the N-terminal region of human and pig-tailed BST-2 proteins, and the BST-2 mutants analyzed in this study.
315A. Ruiz et al. / Virology 406 (2010) 312–321doses (TCID50) (Fig. 5). The percent release of p27 in the context of
each SHIV in the presence and absence of each BST-2 protein is
shown in Fig. 5A. Results and signiﬁcance are expressed and
calculated similar to Fig. 4A. The level of infectious virus released
was determined using TZM-bl indicator cells (Fig. 5B). Again, the
results and signiﬁcance are expressed and calculated as described
for Fig. 4B. Surprisingly, a gradual increase in sensitivity to Vpu was
not observed. We observed that most mutations resulted in BST-2Fig. 3. Expression of parental and mutant BST-2 proteins analyzed in this study. 293 cells w
were collected and the nuclei were removed through centrifugation. The lysates were boiled
analysis using a rabbit polyclonal anti-BST-2 antibody (NIH). Panel A. 293 cells transfected
transfected with vectors expressing pig-tailed parental and mutant BST-2 proteins.sensitivity to HIV-1 Vpu but the level was random in distribution.
Mutations that signiﬁcantly increased sensitivity to Vpu, including
substitution of the leucine at position 41 with an isoleucine, did not
retain this phenotype with additional “humanizing” amino acid
substitutions. This indicates that the substitutions were not
sufﬁcient for the interaction with and antagonism by HIV-1 Vpu
and suggests that their effect on the spatial orientation of the TMD
within the membrane is also important.ere transfected with vectors expressing each of the BST-2 proteins. At 48 h, cell lysates
in sample reducing buffer and protein expression was examined through Western blot
with vectors expressing human parental and mutant BST-2 proteins. Panel B. 293 cells
Fig. 4. BST-2 dependent down-regulation of SHIV virion release from cells transfected with hBST-2 and ptBST-2. Panel A. p27 release assay. 293 cells were co-transfected with vectors
expressing proviral DNA from one of four SHIVs (SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the hBST-2 or ptBST-2 protein. At 48 h post-
transfection, the supernatants and cell lysates were collected and cleared of cellular debris and nuclei by centrifugation. The p27 content of both the supernatant and cell lysate from
each sample was quantiﬁed using a p27 antigen capture assay (Zeptometrix) and the percent p27 release calculated. All conditions were run at least three separate times, normalized
to their respective SHIV empty vector controls, and the average percent p27 release and standard error calculated. Signiﬁcance in the restriction of p27 release for the SHIVKU-2MC4
samples was determined with respect to the parental SHIVKU-2MC4 empty vector control using a Student's t-test with pb0.05 considered signiﬁcant (▲). Signiﬁcance in the restriction
of p27 release for the SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/ΔNef samples was calculated with respect to the SHIVKU-2MC4 in the presence of each respective BST-2 using a Student's t-test
with pb0.05 considered signiﬁcant (*). Panel B. Infectious units assay using TZM-bl indicator cells. Supernatants from transfections described above were added to the TZM-bl cells
and serially diluted. At 48 h post-infection, cells were washed, ﬁxed, and stained for 2 h. The TCID50 for each supernatant was calculated based onwells containing cells expressing β-
galactosidase. All conditions were run at least three times and the TCID50 calculated. The average TCID50 and standard error were calculated. Signiﬁcance in the restriction of
infectivity was determined with respect to the parental SHIV empty vector control using a Student's t-test with pb0.05 considered signiﬁcant (•).
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susceptibility to Vpu
Our results shown in Fig. 5 indicated that insertion of the two
residues in the transmembrane domain of ptBST-2 alone signiﬁcantly
increased the susceptibility to HIV-1 Vpu. These results were
conﬁrmed by quantifying the level of infectious virus released using
TZM-bl indicator cells (Fig. 5B). These results suggested that the
length of the transmembrane domain may be important for Vpu
antagonism. To test this hypothesis, we generated additional hBST-2
constructs with different amino acid substitutions in the transmem-
brane domain. These constructs included hBST-2 proteins in which
the TMD was replaced with the TMD from ptBST-2 (hBST-2PT-TMD),
the leucine and glycine residues at positions 24 and 25 were
substituted with alanines (hBST-2LG/AA), the residues at positions
24 and 25 were substituted with hydrophobic, isoleucine residues
(hBST-2LG/II), or the two residues were deleted (hBST-2ΔLG). These
plasmids were used in the same virion release assay described above
to determine the percent virion release (Fig. 6A). The hBST-2PT-TMD
protein was no longer susceptible to any viral protein, similar to
results that have been published previously (McNatt et al., 2009;
Douglas et al., 2009). The hBST-2ΔLG protein exhibited similar results
to hBST-2PT-TMD, while the hBST-2LG/AA and hBST-2LG/II proteins
produced results similar to the wild-type protein. These data suggest
that alteration of the length of the transmembrane domain and not
necessarily the hydrophobic nature of the amino acid residues at thesepositions contributed to the resistance to HIV-1 Vpu. These results
were conﬁrmed by quantifying the levels of infectious virus released
using TZM-bl indicator cells (Fig. 6B). The results and signiﬁcance for
both assays are expressed and calculated as described for Fig. 4.
Deletion of residues 13–17 in the ptBST-2 decreases sensitivity to SHIV Nef
In order to study the susceptibility of the ptBST-2 mutants to the
SIVmac Nef protein encoded in our SHIVs, we generated a construct that
expressed a proteinwith a deletion in the regionpreviously shown tobe
sufﬁcient for antagonism by Nef. Deletion of residues 13–17 within this
region (ptBST-2ΔDDIWK) decreased susceptibility of the protein to
SIVmac Nef and resulted in a decrease in p27 released from cells
transfected with all four SHIV constructs (Fig. 5A). These results are in
accordancewith those published previously that residues 14–17within
the rhesus BST-2 protein determine susceptibility to SIVmac Nef. Again,
these results were conﬁrmed using TZM-bl cell assays that indicated a
similar level of infectious virus (Fig. 5B).
Down-regulation of ptBST-2 mutant cell surface expression by Vpu and Nef
We analyzed the ability of Vpu to down-regulate cell surface
expression of hBST-2, ptBST-2 and the ptBST-2mutants. The results in
Fig. 7 show that Vpu caused a down-regulation of hBST-2 and ptBST-2
surface expression of 47% and 14%, respectively. Replacement of the
hBST-2 TMDwith that of ptBST-2 protein (hBST-2PT-TMD) resulted in
Fig. 5. BST-2 dependent down-regulation of SHIV virion release from cells transfected with vectors expressing ptBST-2 mutants. Panel A. p27 release assay. 293 cells were co-
transfected with vectors expressing proviral DNA from one of four SHIVs (SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the hBST-2 or ptBST-2
protein and a vector expressing either the parental or each mutant ptBST-2 protein. At 48 h post-transfection, the supernatants and cell lysates were collected and cleared of cellular
debris and nuclei by centrifugation. The p27 content of both the supernatant and cell lysate from each sample was quantiﬁed using a p27 antigen capture assay (Zeptometrix) and
the percent p27 release calculated. All conditions were run at least three separate times, normalized to their respective SHIV empty vector controls, and the average percent p27
release and standard error calculated. Signiﬁcance in the restriction of p27 release for the SHIVKU-2MC4 samples was determined with respect to the parental SHIVKU-2MC4 empty
vector control using a Student's t-test with pb0.05 considered signiﬁcant (▲). Signiﬁcance in the restriction of p27 release for the SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/ΔNef samples was
calculated with respect to the SHIVKU-2MC4 in the presence of each respective BST-2 using a Student's t-test (*). Panel B. Infectious units assay using TZM-bl indicator cells.
Supernatants from transfections described above were added to the TZM-bl cells and serially diluted. At 48 h post-infection, cells were washed, ﬁxed, and stained for 2 h. The TCID50
for each supernatant was calculated based on wells containing cells expressing β-galactosidase. All conditions were run at least three times and the TCID50 calculated. The average
TCID50 and standard error were calculated. Signiﬁcance in the restriction of infectivity was determined with respect to the parental SHIV empty vector control using a Student's t-test
with pb0.05 considered signiﬁcant (•).
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results indicate that the insertion of a leucine and glycine at positions
29 and 30 (ptBST-2+LG) did not have a substantial effect on surface
down-regulation by Vpu when compared to ptBST-2. We also did not
observe an increase in Vpu-mediated surface down-regulation with
*V28L and V31I mutants. However, continued humanization of the
PTTMD led to a gradual increase in Vpu responsiveness. Exchange of
the ptBST-2 TMD resulted in surface expression levels of 50%, similar
to the hBST-2 in the presence of Vpu. We also analyzed the ability of
the SHIV Nef protein to down-regulate the surface expression of
ptBST-2 and hBST-2. In our hands, the SIV Nef did not signiﬁcantly
down-regulate the surface expression of either hBST-2 or ptBST-2
proteins (data not shown).
Discussion
Previous studies have shown that BST-2 restricts HIV-1 and SIVmac in a
species-speciﬁc manner with these effects being counteracted by HIV-1
Vpu and SIV Nef (Jia et al., 2009;McNatt et al., 2009; Neil et al., 2008; Van
Damme et al., 2008; Zhang et al., 2009). SHIVs that express both of
theseproteins havebeenusedextensively to study the effects of these and
other viral proteins in vivo. Thus, one goal of these studies was to
determine if SHIVs would counter human and pig-tailed BST-2 proteins
and if speciﬁc mutations in these primate BST-2 proteins would increaseor decrease sensitivity to Vpu and Nef. We approached this by character-
izingBST-2-mediated restriction of theunmodiﬁedSHIVKU-2MC4 and three
additional SHIVs thatdidnotexpressVpu,Neforbothproteins.Our results
demonstrate that SHIVs display similar properties as HIV-1 and SIV with
respect to human and pig-tailed BST-2. That is, SHIVΔVpu was restricted
by hBST-2 while SHIVΔNef was inhibited by ptBST-2. This suggests that
the amino acid substitutions in the Nef protein during adaptation of
SHIVKU-2MC4 to cause disease in rhesus and pig-tailed macaques did not
result in a loss of Nef antagonism against ptBST-2.
The resistance of the ptBST-2 to SHIV Vpu and its sensitivity to SHIV
Nef allowed us to characterize the role of individual residues within the
transmembrane domain of the ptBST-2 associated with these properties.
While previous studies presented data on the role of the individual
residues of the hBST-2 TMD, we used a series of sequential amino acid
substitutions to “humanize” the ptBST-2 TMD (Gupta et al., 2009;McNatt
et al., 2009; Rong et al., 2009). Our results are in accordance with these
groups in that the two amino acid deletions in the ptBST-2 TMD (L29 and
G30) are key residues involved in the susceptibility to HIV-1 Vpu. How-
ever, our analysis of a series of proteins with a progressive “humanizing”
of the TMD revealed a ﬂuctuation in sensitivity to HIV-1 Vpu. All of the
ptBST-2 transmembrane domain mutants displayed susceptibility to
either HIV-1 Vpu, SIV Nef or both. However, the four mutations that dis-
played themost interesting effectswere ptBST-2(+LG), ptBST-2(*G35V),
ptBST-2(*V38I) and ptBST-2(*L41I). Insertion of the leucine and glycine
Fig. 6. BST-2 dependent down-regulation of SHIV virion release from cells transfected with vectors expressing hBST-2 mutants. Panel A. p27 release assay. 293 cells were co-
transfected with vectors expressing proviral DNA from one of four SHIVs (SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef or SHIVΔVpu/ΔNef) and a vector expressing either the hBST-2 or ptBST-2
protein and a vector expressing either the parental or each mutant hBST-2 protein. At 48 h post-transfection, the supernatants and cell lysates were collected and cleared of cellular
debris and nuclei by centrifugation. The p27 content of both the supernatant and cell lysate from each sample was quantiﬁed using a p27 antigen capture assay (Zeptometrix) and
the percent p27 release calculated. All conditions were run at least three separate times, normalized to their respective SHIV empty vector controls, and the average percent p27
release and standard error calculated. Signiﬁcance in the restriction of p27 release for the SHIVKU-2MC4 samples was determined with respect to the parental SHIVKU-2MC4 empty
vector control using a Student's t-test with pb0.05 considered signiﬁcant (▲). Signiﬁcance in the restriction of p27 release for the SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/ΔNef samples was
calculated with respect to the SHIVKU-2MC4 in the presence of each respective BST-2 using a Student's t-test (*). Panel B. Infectious units assay using TZM-bl indicator cells.
Supernatants from transfections described above were added to the TZM-bl cells and serially diluted. At 48 h post-infection, cells were washed, ﬁxed, and stained for 2 h. The TCID50
for each supernatant was calculated based on wells containing cells expressing β-galactosidase. All conditions were run at least three times and the TCID50 calculated. The average
TCID50 and standard error were calculated. Signiﬁcance in the restriction of infectivity was determined with respect to the parental SHIV empty vector control using a Student's t-test
with pb0.05 considered signiﬁcant (•).
Fig. 7. The down-regulation of cell surface expression of ptBST-2 mutants by Vpu. Tomeasure surface down-regulation of BST-2mutants in the presence of HIV-1 Vpu, 293 cells were
seeded on a 12-well format and transfected using Lipofectamine 2000. For each transfection, 0.25 μg of pCG-GFP, 0.5 μg of pVphu or mock DNA plasmid, and 0.06 μg of each BST-2
noted above were used. At 24 h, the cells were reacted with a mouse anti-HM1.24 antibody, then with an APC-conjugated goat anti-mouse antibody, followed by ﬁxation. The cells
were analyzed by two-color ﬂow cytometry. For each BST-2mutant, the APCmean ﬂuorescent intensity (MFI) of high GFP expressing cells in the presence of Vphuwas normalized to
the MFI of cells without Vphu. The data are represented as percent BST-2 remaining on the surface of transfected cells in the presence of Vphu. All conditions were run at least twice
and the standard deviation calculated.
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HIV-1 Vpu without signiﬁcantly altering the susceptibility to SIV Nef.
Substitution of the glycine at position 35 with a valine eliminated the
sensitivity to SHIV Vpu gained with the preceding mutations. This
substitution also seemed to eliminate sensitivity to SHIV Nef. Mutation of
the valine at position 38 to an isoleucine resulted in a complete loss of the
sensitivity to HIV-1 Vpu gained with mutation of the preceding residues,
butagainwithout alterationof SHIVNef susceptibility. Finally, substitution
of the leucine at position 41 with an isoleucine resulted in an increased
sensitivity to HIV-1 Vpu and an increase in the additive effects of Vpu and
Nef. Any alterations in Nef susceptibility observed with the transmem-
brane domain mutations are most likely due to an alteration in the
positioning of the cytoplasmic tail along the membrane. These results
suggest that the overall structure, the spatial orientation of amino acids in
themembrane, or possibly the tilt angle of the TMD in themembranemay
be important factors. Insertion of the leucine and glycine at positions 29
and 30 into the ptBST-2 resulted in the most observable effect on the
antagonism by Vpu leading us to hypothesize that the length of the
transmembranedomainwas important for this interaction.We tested this
hypothesis by constructing three mutants of hBST-2 with either deletion
of the LG (ΔLG), or substitution with amino acids with either a small
hydrophobic side group (LG/AA) or a larger hydrophobic side group (LG/
II). The hBST-2ΔLG deletion restricted particle release of all four SHIVs
tested, while the LG/AA and LG/II mutants remained highly sensitive to
Vpu and resistant toNef. These results indicate that the length andnot the
degree of hydrophobicity of these amino acids is critical in deﬁning
susceptibility to HIV-1 Vpu. For these “humanized” ptBST-2 mutants,
down-regulation of surface expression by HIV-1 Vpu generally correlated
with the relief of restriction, with some exceptions. For example, wt
ptBST-2 was minimally down-regulated by Vpu, but when ptBST-2
contained the TMD of hBST-2 it was efﬁciently down-regulated.
Conversely, the huBST-2 mutant that contained the TMD of ptBST-2 was
not down-regulated by Vpu. These results are consistent with the data on
p27 release. A gradual increase in Vpu-mediated surface down-regulation
was observed with sequential humanization of the ptTMD, and a
reduction of ptBST-2 surface expression to levels similar to those of
hBST-2 in response to Vpu was observed when the TMD was exchanged
with that of hBST-2. These results generally correlated with p27 release
detected with the SHIVΔVpu/ΔNef. However, the surface down-regulation
data did not perfectly correlate with the results of p27 release. For
example, the effect of Vpu on the surface expression of the ptBST(*L41I)
mutant is less than expected based on the p27 release data. These results
suggest that the hBST-2 transmembrane domain is involved in Vpu-
mediated surface down-regulation, however it may not be sufﬁcient to
fully explain the anti-viral properties or gain in susceptibility of the ptBST-
2 mutants.
The level of surface expression of hBST-2 compared to ptBST-2 is
unknown and it is possible that differences in these levels may help
explain the possible differences in viral restriction efﬁciency as well as
mechanisms of antagonism by viral proteins. Differences in surface
expression could be due to differences in protein expression,
internalization rates and/or turnover rates of each species of protein.
Studies examining these properties are necessary in order to further
elucidate the mechanisms by which different species of BST-2
proteins restrict virion release and how they are antagonized by
different viral proteins. Studies within our laboratory suggest that
there are differences in expression levels of the hBST-2 compared to
the ptBST-2 and present a possible explanation for the differences in
restriction efﬁciency observed in this study (unpublished data).
However, the studies presented herein reﬂect intraspecies analysis
and do not indicate cross-species examination.
This study introduces SHIV as an in vitromodel for studying BST-2
mediated restriction laying a basis for future studies that could lead to
an in vivo model. These results also emphasize the necessity for
studies focused on the structural components of BST-2 and their
contributions to the anti-viral properties of the protein. These studiessupport the ﬁndings by Perez-Caballero et al. (2009) that the amino
acid identity of the protein is less signiﬁcant than the structural
properties in virion restriction. Taken together, these results provide a
basis for the development of new small molecule inhibitors designed
to mimic the effects of BST-2 on multiple enveloped viruses.
The physiological relevance of the anti-HIV activity of BST-2 has
not yet been indicate in vivo. Previously published studies from our
laboratory indicate that a functional Vpu protein is important for
pathogenicity of SHIV in the pig-tailed macaque model, which
expresses a Vpu resistant BST-2, suggesting a role for other functions
of Vpu in viral pathogenesis (Hout et al., 2005;McCormick-Davis et al.,
2000; Singh et al., 2001; Singh et al., 2003; Stephens et al., 2002). Of
note are our studies using a SHIV expressing the VpuM2 protein
(SHIVM2). This protein has been shown to down-regulate CD4 from
the surface of CD4+ cells, however it is unable to rescue virion release
from cells expressing high levels of BST-2 (data not shown). SHIVM2
caused a loss of CD4+ T cells within one month, high viral loads and
histological lesions in infected macaques (Hout, et al., 2006). These
studies provide evidence for additional functions of the Vpu
transmembrane domain in vivo unrelated to BST-2 antagonism,
which are potentially related to the ion channel properties exhibited
by Vpu. Just as the BST-2 TM domain has amino acids/structures that
are critical for interactions with Vpu, there are most likely amino acids
within the Vpu TM domain that are also critical for these interactions.
It will be of interest to identify these residues and determine if they
are conserved in different subtypes of HIV-1.
Materials and methods
Plasmid construction
The human bst-2 (hBST-2) gene was ampliﬁed from a plasmid
expressing a full length cDNA of hBST-2 (Origene) using oligonucleo-
tides containing 5′ BamHI and 3′ XhoI sites. The fragment was ligated
into a pcDNA3.1(+) expression vector (Promega) digested with
BamHI and XhoI restriction enzymes. The plasmid was sequenced to
ensure no mutations were introduced during the cloning process. The
pig-tailed bst-2 (ptBST-2) and rhesus bst-2 (rhBST-2) genes were
ampliﬁed from cDNA generated from PBMC isolated from uninfected
juvenile pig-tailed and rhesus macaques using a reverse-transcriptase
polymerase chain reaction (RT-PCR). Oligonucleotides used contained
5′ BamHI and 3′ NotI restriction sites. The resulting fragment was
ligated into a pcDNA3.1(+) expression vector (Promega) digested
with BamHI and NotI restriction enzymes. Mutations introduced into
all plasmids were accomplished using a QuikChange site-directed
mutagenesis kit (Stratagene) according to the manufacturer's proto-
col. All plasmids were sequenced to ensure the validity of the
mutations and that no other mutations were introduced during the
cloning process. The pcVphu construct was kindly provided by the
NIH AIDS Research and Reference Reagent Program.
Sequence analysis of ptBST-2 and rhBST-2 variants
The bst-2 gene was ampliﬁed from ﬁve and seven different rhesus
and pig-tailed macaque spleen tissues or PBMC, respectively, using a
one-tube Titan reverse-transcriptase kit (Roche). The resulting
fragments were puriﬁed using a Qiaquick Gel Extraction kit (Qiagen)
and subjected to sequence analysis.
Proviral DNA plasmid construction
The construction of molecular clone SHIVKU-2MC4 has been described
previously (Liu et al., 1999). In order to construct SHIVΔVpu, SHIVΔNef,
and SHIVΔVpu/ΔNef anothermolecular cloneΔvpuΔnefSHIVPPcwas used
and the construction of this clone has been described previously (Joag
et al., 1998). A 1444 base pair fragmentwas removed from SHIVKU-2MC4
320 A. Ruiz et al. / Virology 406 (2010) 312–321using restriction enzymes SphI and NheI. This fragment was replaced
with the corresponding 1382 basepair fragment of ΔvpuΔnefSHIVPPc.
The resulting construct expressed a Vpu protein with a 62 base pair
deletion and an inactive start codon (SHIVΔVpu). A 525 base pair
fragment was removed from SHIVKU-2MC4 using restriction enzymes
BamHI and NcoI. This fragment which encoded for part of the gp41 and
nef genes was replaced with the corresponding 321 base pair fragment
ofΔvpuΔnefSHIVPPc. The resulting construct expressed a nef genewith
a 204 base pair deletion that included the start codon (SHIVΔNef). A 525
base pair fragment was removed from SHIVΔVpu using restriction
enzymes BamHI and NcoI. This fragment which encoded for part of the
gp41 and nef genes was replaced with the corresponding 321 base pair
fragment ofΔvpuΔnef SHIVPPc. The resulting construct expressed a vpu
gene with a 62 base pair deletion and an inactive start codon and a nef
gene with a 204 base pair deletion that included the start codon
(SHIVΔVpu/ΔNef).
Cell lines and transfections
The HEK 293 and TZM-bl cell lines were maintained in Dulbecco's
minimal essential medium supplemented with 10% fetal bovine
serum (FBS), gentamicin (5 μg per ml) and penicillin/streptomycin
(100U/100 μg per ml). Both cell lines were transfected using a
cationic polymer (polyethylenimine) transfection reagent (ExGen™
500, MBI Fermentas) using themanufacturer's protocol. 293 cells used
for surface expression studies were maintained in Eagle's minimal
essential medium (Quality Biological) supplemented with 10% FBS
and 1× L-glutamine and were transfected using Lipofetamine 2000
(Invitrogen) according to manufacturer-provided instructions.
Western blot assays
Human 293 cells (105) were seeded into a 24-well tissue culture
plate 24 h prior to transfection. Cells were transfected as described
above with 1 μg of plasmid expressing full length SHIV proviral DNA
(either SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef, and/or SHIVΔVpu/ΔNef) and
empty vector or 10 ng of plasmid expressing various untagged bst-2
genes. Cells were incubated at 37 °C in 5% CO2 atmosphere for 48 h.
Cells were lysed in 200 μl of 1× RIPA buffer (50 mM Tris–HCl, pH 7.5;
50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA) and the
nuclei removed through high speed centrifugation. Cell lysates were
made 1× with sample reducing buffer (100 mM Tris–HCl pH 6.8, 30%
glycerol, 2% SDS, 10% 2-mercaptoethanol, 0.05% bromophenol blue)
and boiled for 5 min. Samples were separated on SDS-PAGE gels and
transferred to PVDF membrane. BST-2 proteins were detected using a
rabbit polyclonal anti-BST-2 primary antibody kindly provided by the
NIH AIDS Research and Reference Reagent Program (1:1000 dilution).
The secondary antibody used was an alkaline phosphatase-conjugat-
ed goat anti-rabbit IgG (whole molecule) (Sigma). Alkaline phospha-
tase substrate used was CDP-Star (Sigma) for chemiluminescent
detection and an LAS-4000 Imager (Fujiﬁlm) was used for the
visualization and analysis of proteins.
Virion release assays
293 cells (105) were seeded into a 24-well tissue culture plate 24 h
prior to transfection. Cells were transfected as described above with
1 μg of plasmid expressing full length SHIV proviral DNA (either
SHIVKU-2MC4, SHIVΔVpu, SHIVΔNef, or SHIVΔVpu/ΔNef) and 10 ng of
plasmid expressing various untagged bst-2 genes. Cells were
incubated at 37 °C in 5% CO2 atmosphere for 48 h. Supernatants
were collected and cellular debris removed through low speed
centrifugation. Cells were lysed in 200 μl of 1× RIPA buffer (50 mM
Tris–HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM
EDTA) and the nuclei removed through high speed centrifugation. The
amount of p27 present within the virion containing supernatant andthe cell lysates was determined using a commercially available p27
ELISA kit (Zeptometrix Incorporated) and percent p27 release
calculated. All conditions were run at least three separate times,
normalized to the empty vector control, and the average percent p27
release and standard error calculated. Signiﬁcance in the restriction of
p27 release for the SHIVKU-2MC4 samples was determined with respect
to the parental SHIVKU-2MC4 empty vector control using a Student's t-
test with pb0.05 considered signiﬁcant (▴). Signiﬁcance in the
restriction of p27 release for the SHIVΔVpu, SHIVΔNef, and SHIVΔVpu/
ΔNef samples was calculated with respect to the SHIVKU-2MC4 in the
presence of each respective BST-2 using a Student's t-test with pb0.05
considered signiﬁcant (*).
Infectious particle release assays
TZM-bl cells (104) expressing luciferase and β-galactosidase genes
under the control of an HIV-1 promoter were seeded into a 96-well
tissue culture plate 24 h prior to infection. Supernatants collected
from the 293 cells co-transfected with SHIV and BST-2 expressing
plasmids as described above were added to the TZM-bl cells and
serially diluted. At 48 h post-infection, cells were washed twice in 1×
PBS and incubated in a ﬁxative solution (0.25% glutaraldehyde, 0.8%
formaldehyde in phosphate-buffered saline) for 5 min at room
temperature. The cells were washed three times in 1× PBS and
covered in staining solution (400 μg/ml X-gal, 4 mM MgCl2, 4 mM
K3Fe(CN)6, 4 mM K4Fe(CN)6–3H2O in phosphate-buffered saline) and
incubated for 2 h at 37 °C. Cells were washed once in 1× PBS and then
covered in 1× PBS during counting. The TCID50 for each supernatant
was calculated based on wells containing cells expressing β-
galactosidase. All conditions were run at least three times and the
TCID50 calculated. The average TCID50 and standard error were
calculated. Signiﬁcance in the restriction of infectivity was deter-
mined with respect to the parental SHIV empty vector control using a
Student's t-test with pb0.05 considered signiﬁcant (•).
BST-2 surface expression assays
For surface down-regulation of BST-2 mutants in the presence of
HIV-1 Vpu, 106 293 cells were seeded on a 12-well format and
transfected using Lipofectamine 2000. For each transfection, 0.25 μg of
pCG-GFP, 0.5 μg of pVphu or mock DNA plasmid, and 0.06 μg of each
BST-2 noted above were used. After 24 h, the cells were stained with
mouse anti-HM1.24 antibody (Chugai) at a concentration of 10 μg/ml,
at 4 °C in phosphate-buffered saline (PBS) with 0.1% sodium azide and
2% fetal bovine serum, followed by APC-conjugated goat anti-mouse
antibody (Biolegend) at 10 μg/ml in the same staining buffer, then
ﬁxed with 1% paraformaldehyde. The cells were analyzed by two-
color ﬂow cytometry. For each BST-2 mutant, the APC mean
ﬂuorescent intensity (MFI) of high GFP expressing cells in the
presence of Vphu was normalized to the MFI of cells without Vphu.
The data are represented as percent BST-2 remaining on the surface of
transfected cells in the presence of Vphu. All conditions were run at
least twice and the standard deviation calculated.
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